Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

72.62 USD -2.00 (-2.68%)
Official Closing Price Updated: 7:59 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
79 80 Next >
Merck to Present at the 39th Annual J.P. Morgan Healthcare Conference
Merck to Present at J.P. Morgan Healthcare Conference 
From Business Wire News Releases
LYNPARZA® (olaparib) Receives Three New Approvals in Japan
LYNPARZA® (olaparib) Receives Three New Approvals in Japan 
From Business Wire News Releases
Thinking about trading options or stock in Apple, Caesars Entertainment, Merck, AT&T, or FireEye?
InvestorsObserver issues critical PriceWatch Alerts for AAPL, CZR, MRK, T, and FEYE. 
From PR Newswire
Merck Announces Supply Agreement with U.S. Government for Initial Doses of Investigational Biological Therapy for the Treatment of Patients with Severe and Critical COVID-19
Merck Announces Supply Agreement with U.S. Government for Doses of Investigational Biological Therapy for the Treatment of Patients with COVID-19 
From Business Wire News Releases
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic
FDA Grants Priority Review to KEYTRUDA Plus Chemotherapy as 1L Treatment for Locally Advanced Unresectable or Metastatic Esophageal and GEJ Cancer 
From Business Wire News Releases
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Ch
KEYTRUDA Plus LENVIMA Demonstrated Statistically Significant Improvement in OS, PFS and ORR vs Chemotherapy in Advanced Endometrial Cancer 
From Business Wire News Releases
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as First-Line Treatment in Adult Patients With Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dM
Merck Receives Positive EU CHMP Opinion for KEYTRUDA as First-Line Treatment in Adult Patients With Metastatic MSI-H or dMMR Colorectal Cancer 
From Business Wire News Releases
BetterInvesting™ Magazine Chooses United Rentals As "Growth" Stock and Merck As "Undervalued" For March 2021 Issue
The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced United Rentals Inc. (NYSE: URI) as its "Stock to Study" and Merck & Co., Inc. (NYSE: MRK) its... 
From PR Newswire
New Pharma Trials Making Big Gains in Fight Against Triple-Negative Breast Cancer (TNBC)
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
New Pharma Trials Making Big Gains in Fight Against Triple-Negative Breast Cancer (TNBC)
FN Media Group Presents USA News Group News Commentary 
From PR Newswire
This Ancient Aztec Medicine Could Be A Gamechanger For Mental Health
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
This Ancient Aztec Medicine Could Be A Gamechanger For Mental Health
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary 
From PR Newswire
Merck to Present at the 2020 Evercore ISI 3rd Annual HealthCONx Virtual Conference
Merck to Present at the 2020 Evercore ISI 3rd Annual HealthCONx Virtual Conference 
From Business Wire News Releases
Thinking about trading options or stock in Apple, Merck, Solaredge Technologies, Roku, or Norwegian Cruise Line?
InvestorsObserver issues critical PriceWatch Alerts for AAPL, MRK, SEDG, ROKU, and NCLH. 
From PR Newswire
Merck Animal Health Survey Reveals First-Time Dog Owners Need Support
Veterinarians Offer Tips to Embrace Pet Care for Life 
From PR Newswire
Merck Submits Applications for Licensure of V114, the Company’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults to the U.S. FDA and European Medicines Agency
Merck Submits Applications for Licensure of V114, the Company’s Investigational 15-valent Pneumococcal Conjugate Vaccine, to the U.S. FDA and EMA 
From Business Wire News Releases
Merck to Acquire OncoImmune
Merck to Acquire OncoImmune 
From Business Wire News Releases
Global Acute Myeloid Leukemia Therapeutics Market Could Exceed $3.5 Billion By 2027
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Acute Myeloid Leukemia Therapeutics Market Could Exceed $3.5 Billion By 2027
Financialnewsmedia.com News Commentary 
From PR Newswire
Merck Announces First-Quarter 2021 Dividend
Merck Announces First-Quarter 2021 Dividend 
From Business Wire News Releases
Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1
Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1 
From Business Wire News Releases
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1
FDA Approves KEYTRUDA Plus Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic TNBC Whose Tumors Express PD-L1 (CPS ≥10) 
From Business Wire News Releases
Surface Oncology Announces SRF617 and SRF388 Will Advance to Combination and Expansion Stages of Ongoing Phase 1 Clinical Trials
From GlobeNewswire News Releases
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Vers
KEYTRUDA Plus LENVIMA Demonstrated Statistically Significant Improvement Versus Sunitinib as First-Line Treatment for Patients With Advanced RCC 
From Business Wire News Releases
Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Stop
Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients 
From Business Wire News Releases
Biotech Brief: Breast Cancer Drug Market Could Exceed $38 Billion By 2025
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Biotech Brief: Breast Cancer Drug Market Could Exceed $38 Billion By 2025
Financialnewsmedia.com News Commentary 
From PR Newswire
Thinking about trading options or stock in General Electric, Merck, Roku, Canopy Growth Corp, or Upwork?
InvestorsObserver issues critical PriceWatch Alerts for GE, MRK, ROKU, CGC, and UPWK. 
From PR Newswire
Pappas Capital Portfolio Company VelosBio to be Acquired by Merck
Pappas Capital, a leading venture capital firm focused on advancing life sciences, today announced that its portfolio company, VelosBio Inc. ("VelosBio" or the "Company"), has entered into a definitive... 
From PR Newswire
LYNPARZA® (olaparib) Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
LYNPARZA® (olaparib) Approved in the EU for Treatment of BRCA12-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
79 80 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account